SugitaniI, ItoY, TakeuchiD, et al.Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. Thyroid, 2021; 31(2):183–192; doi: 10.1089/thy.2020.0330
2.
TuttleRM, ZhangL, ShahaA. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab, 2018; 13(2):77–85; doi: 10.1080/17446651.2018.1449641
3.
YamamotoM, MiyauchiA, ItoY, et al.Active Surveillance Outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroxine treatment status. Thyroid, 2023; 33(10):1182–1189; doi: 10.1089/thy.2023.0046
4.
RyuYJ, YoonJH. Chronic lymphocytic thyroiditis protects against recurrence in patients with cN0 papillary thyroid cancer. Surg Oncol, 2020; 34:67–73; doi: 10.1016/j.suronc.2020.03.008
5.
TuttleRM, FaginJA, MinkowitzG, et al.Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg, 2017; 143(10):1015–1020; doi: 10.1001/jamaoto.2017.1442
6.
ItoY, MiyauchiA, FujishimaM, et al.Thyroid-stimulating hormone, age, and tumor size are risk factors for progression during active surveillance of low-risk papillary thyroid microcarcinoma in adults. World J Surg, 2023; 47(2):392–401; doi: 10.1007/s00268-022-06770-z
7.
ItoY, MiyauchiA, KiharaM, et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid, 2014; 24(1):27–34; doi: 10.1089/thy.2013.0367
8.
KimHI, JangHW, AhnHS, et al.High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J Clin Endocrinol Metab, 2018; 103(2):446–451; doi: 10.1210/jc.2017-01775
9.
SugitaniI, FujimotoY, YamadaK. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg, 2014; 38(3):673–678; doi: 10.1007/s00268-013-2335-8
10.
TuttleRM, FaginJ, MinkowitzG, et al.Active surveillance of papillary thyroid cancer: Frequency and time course of the six most common tumor volume kinetic patterns. Thyroid, 2022; 32(11):1337–1345; doi: 10.1089/thy.2022.0325
11.
TsaiK, LeungAM. Subclinical hyperthyroidism: A review of the clinical literature. Endocr Pract, 2021; 27(3):254–260; doi: 10.1016/j.eprac.2021.02.002
12.
WangLY, SmithAW, PalmerFL, et al.Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid, 2015; 25(3):300–307; doi: 10.1089/thy.2014.0287
13.
JonklaasJ. Role of levothyroxine/liothyronine combinations in treating hypothyroidism. Endocrinol Metab Clin North Am, 2022; 51(2):243–263; doi: 10.1016/j.ecl.2021.12.003
14.
SomwaruLL, ArnoldAM, JoshiN, et al.High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab, 2009; 94(4):1342–1345; doi: 10.1210/jc.2008-1696
15.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016; 26(1):1–133; doi: 10.1089/thy.2015.0020
16.
Herrera-PerezD, HaslamA, CrainT, et al.A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Elife, 2019; 8:45183; doi: 10.7554/eLife.45183
